Invesco Nasdaq Biotechnology ETF (IBBQ)

$23.15 +0.14 (0.61%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 3,692
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq compiles the underlying index, which is a modified market capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The index may include securities of large-, mid- and small-capita...

Night_Owl_Biotech
Night_Owl_Biotech May. 8 at 5:07 PM
$TARS fully diluted market cap & enterprise value using TARS 3/31/26 cap table @ $60.87 per share. The 2nd attachment compares TARS' valuation related data points to 7 peers acquired 25-91 months post FDA approval (34 months for TARS). Note these TARS hypothetical peers were acquired for 0.86-0.93X 5-year revenues (some higher) and/or 0.31-0.37X 10-year revenue forecasts. If TARS analyst consensus revenue ests are credible AND if TARS were hypothetically acquired for 0.88X 5-year revenues and/or 0.32 10-year (2 HUGE IFs), TARS hypothetical M&A EV would be ~$4.3-$4.5B or, with $300MM net cash/debt, ~$4.6-$4.8B in market cap. With just under 50MM fully diluted shares o/s this would be $92-$96 per share. We're merely sharing "what-if" analysis using TARS 3/31/26 cap table & analyst consensus. This is not investment advice because we have no idea what TARS might be worth in a M&A exit. We're curious if investors believe a hypothetical TARS M&A multiple would be higher or lower $XBI $IBBQ
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 8 at 12:41 PM
$VSTM The graph compares VSTM actual product sales for its first 3 full quarters post FDA approval to the same for CTIC's Vonjo cancer therapy & ZGNX's rare disease therapy called Fintepla. Both CTIC & ZGNX were 1 product companies with no meaningful pipeline. Both were acquired for enterprise values of $1.7B. VSTM does have a pipeline referred to VS-7375 that is about to enroll patients in 3 registrational trials for certain solid tumors that express the KRAS 12D mutation. Do your own research but the TAM is gargantuan. We suspect VSTM will partner 7375 with a Big Pharma. Also attached is VSTM's fully diluted cap table. VSTM has roughly 12MM pre-funded warrants that most stock screeners do not consider when posting valuation data. This is not investment advice. We're merely sharing analysis. $XBI $IBB $IBBQ
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 7 at 3:21 PM
$MDGL fully diluted market cap & enterprise value at $525 per share using MDGL's 3/31/2026 cap table (that does not consider share grants & other activity post 3/31/2026). MDGL fully diluted shares outstanding are roughly 33% higher than traditional shares outstanding. It's our experience fully diluted shares are usually 10-15% higher for most MDGL peers. This is an important consideration when assessing hypothetical MDGL M&A exit valuations. The attachment provides hypothetical MDGL fully diluted valuations up to $650 per share. We'd suggest investors use 31MM fully diluted MDGL shares when assessing hypothetical M&A exit valuations. This is not investment advice. We have no idea what MDGL might be worth in a hypothetical acquisition. $XBI $IBB $IBBQ
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 1 at 10:40 AM
$IBBQ RSI: 51.04, MACD: 0.0371 Vol: 0.55, MA20: 29.54, MA50: 29.18 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 4:13 PM
$IBBQ RSI: 58.04, MACD: 0.2567 Vol: 0.33, MA20: 29.55, MA50: 29.11 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 9:56 AM
$IBBQ Current Stock Price: $29.41
0 · Reply
TrojanTitan
TrojanTitan Dec. 26 at 1:42 PM
$IBBQ Risk appetite is present but conditioned on validation. Cash efficiency must trend upward while maintaining strategic flexibility. Sustained traction could validate the investment case. Stronger outcomes appear only when priorities stay focused.
0 · Reply
Reanimated666
Reanimated666 Dec. 23 at 1:59 PM
$IBBQ This can be at 50 bucks this time next year
0 · Reply
Twinity
Twinity Nov. 26 at 2:18 PM
$XBI $IBB $IBBQ $LABU $LABD some say that AI helps BigPharma.. sure, for drug discovery and such.. however it doesn't buy them time one cannot speed up Human Trials! lots of patents come to end, that's why we have seen the MA spree.. but with recent drug cuts, so the profits go busted generics don't make them rich just saying..
0 · Reply
Twinity
Twinity Nov. 26 at 1:34 PM
$IBB $IBBQ Centers for Medicare and Medicaid Services (CMS) has revealed HUGE price cuts on drugs, ranging between 38% and 85% for a 30-day supply vs 2024 https://pharmaphorum.com/news/latest-medicare-pricing-cuts-promise-12bn-savings
0 · Reply
Latest News on IBBQ
No data available.
Night_Owl_Biotech
Night_Owl_Biotech May. 8 at 5:07 PM
$TARS fully diluted market cap & enterprise value using TARS 3/31/26 cap table @ $60.87 per share. The 2nd attachment compares TARS' valuation related data points to 7 peers acquired 25-91 months post FDA approval (34 months for TARS). Note these TARS hypothetical peers were acquired for 0.86-0.93X 5-year revenues (some higher) and/or 0.31-0.37X 10-year revenue forecasts. If TARS analyst consensus revenue ests are credible AND if TARS were hypothetically acquired for 0.88X 5-year revenues and/or 0.32 10-year (2 HUGE IFs), TARS hypothetical M&A EV would be ~$4.3-$4.5B or, with $300MM net cash/debt, ~$4.6-$4.8B in market cap. With just under 50MM fully diluted shares o/s this would be $92-$96 per share. We're merely sharing "what-if" analysis using TARS 3/31/26 cap table & analyst consensus. This is not investment advice because we have no idea what TARS might be worth in a M&A exit. We're curious if investors believe a hypothetical TARS M&A multiple would be higher or lower $XBI $IBBQ
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 8 at 12:41 PM
$VSTM The graph compares VSTM actual product sales for its first 3 full quarters post FDA approval to the same for CTIC's Vonjo cancer therapy & ZGNX's rare disease therapy called Fintepla. Both CTIC & ZGNX were 1 product companies with no meaningful pipeline. Both were acquired for enterprise values of $1.7B. VSTM does have a pipeline referred to VS-7375 that is about to enroll patients in 3 registrational trials for certain solid tumors that express the KRAS 12D mutation. Do your own research but the TAM is gargantuan. We suspect VSTM will partner 7375 with a Big Pharma. Also attached is VSTM's fully diluted cap table. VSTM has roughly 12MM pre-funded warrants that most stock screeners do not consider when posting valuation data. This is not investment advice. We're merely sharing analysis. $XBI $IBB $IBBQ
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 7 at 3:21 PM
$MDGL fully diluted market cap & enterprise value at $525 per share using MDGL's 3/31/2026 cap table (that does not consider share grants & other activity post 3/31/2026). MDGL fully diluted shares outstanding are roughly 33% higher than traditional shares outstanding. It's our experience fully diluted shares are usually 10-15% higher for most MDGL peers. This is an important consideration when assessing hypothetical MDGL M&A exit valuations. The attachment provides hypothetical MDGL fully diluted valuations up to $650 per share. We'd suggest investors use 31MM fully diluted MDGL shares when assessing hypothetical M&A exit valuations. This is not investment advice. We have no idea what MDGL might be worth in a hypothetical acquisition. $XBI $IBB $IBBQ
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 1 at 10:40 AM
$IBBQ RSI: 51.04, MACD: 0.0371 Vol: 0.55, MA20: 29.54, MA50: 29.18 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 4:13 PM
$IBBQ RSI: 58.04, MACD: 0.2567 Vol: 0.33, MA20: 29.55, MA50: 29.11 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 9:56 AM
$IBBQ Current Stock Price: $29.41
0 · Reply
TrojanTitan
TrojanTitan Dec. 26 at 1:42 PM
$IBBQ Risk appetite is present but conditioned on validation. Cash efficiency must trend upward while maintaining strategic flexibility. Sustained traction could validate the investment case. Stronger outcomes appear only when priorities stay focused.
0 · Reply
Reanimated666
Reanimated666 Dec. 23 at 1:59 PM
$IBBQ This can be at 50 bucks this time next year
0 · Reply
Twinity
Twinity Nov. 26 at 2:18 PM
$XBI $IBB $IBBQ $LABU $LABD some say that AI helps BigPharma.. sure, for drug discovery and such.. however it doesn't buy them time one cannot speed up Human Trials! lots of patents come to end, that's why we have seen the MA spree.. but with recent drug cuts, so the profits go busted generics don't make them rich just saying..
0 · Reply
Twinity
Twinity Nov. 26 at 1:34 PM
$IBB $IBBQ Centers for Medicare and Medicaid Services (CMS) has revealed HUGE price cuts on drugs, ranging between 38% and 85% for a 30-day supply vs 2024 https://pharmaphorum.com/news/latest-medicare-pricing-cuts-promise-12bn-savings
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 24 at 11:56 AM
Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug $ALVO $IBBQ $PRFZ https://stocktwits.com/news/equity/markets/alvotech-drug-approved-in-europe-as-biosimilar-for-bone-disease-drugs/cL5bIelREQc
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 20 at 12:33 PM
Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options $APLT $VTI $IBBQ https://stocktwits.com/news/equity/markets/applied-therapeutics-to-lay-off-nearly-half-its-staff-board-explores-m-and-a-options/cLPAinqRE96
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 3 at 4:01 PM
uniQure Stock Tumbled 56% Today: What’s The FDA Angle? $QURE $FRTY $IBBQ https://stocktwits.com/news/equity/markets/uniqure-stock-tumbles-after-fda-meeting/cL2NBqhR3zq
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 1 at 5:21 PM
The attachment compares the enterprise values paid in 6 $SNDX peer M&A transactions. We define peers as comm'l-stage bios (oncology & non) whose products are projected to generate the same revenues. Note SNDX trades at 0.10X cumulative 10-year revenues v. the 6 peers were acquired for 0.26 - 0.39X 10-year revenues. Even excluding the highest SNDX analyst revenue estimate for each year, SNDX trades @ 0.16X 10-year revenues. Because generated 96% gross profit margins on their revenues YTD suggests, all other things being equal, SNDX's merits a premium revenue multiple. Of course there could be other data points offsetting a premium multiple. Gross profit margin is just 1 to consider. See our post yesterday that shows SNDX also trades @ the lowest multiple of actual product revenues post launch v. a meaningful pool of peers generating like sales $ This is not investment advice. SNDX reports Q3 25 results Monday. A bad report may adversely affect SNDX's share price. $INCY $IBB $IBBQ $XBI
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 5:34 PM
@outlawinvestor1 FYI $MRUS filed their 14D9 this morning that includes, among other things, the revenue forecast provided $GMAB as part of the broader financial projections. You were definitely right again. The MRUS forecasts, especially in the later years, are considerably higher than 3 analysts had projected. I prepared a simple comparison of the 2 showing you snapshots as well. We track these for all commercial-stage bios. It's our experience the projections are closer except for BPMC (BPMC's forecasts were much higher than analysts in the later years). I included an updated comparison of the various revenue multiples versus $PTGX as well. For those interested in clinical-stage bios (and commercial-stage for that matter), may I recommend you follow outlawinvestor1 Otherwise FYI only. This is not investment advice. $IBB $IBBQ
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 17 at 6:58 PM
@outlawinvestor1 Sean I know little about $PRAX except they raised $525MM from investors after publishing the data yesterday. That is an enormous number in any market. Attached is a comparison of PRAX's valuation versus $MRUS & $PTGX using analyst consensus as of yesterday (before the data was published), as of today excluding the most aggressive forecast and "consensus" that includes the most aggressive forecast. You see PRAX trades at a much lower multiple since revenues are not forecast for some time. Seems to me PRAX is a value should they move forward but I otherwise dislike clinical-stage bio & was hoping you'd take a quick look...or any investor familiar with PRAX. This is not investment advice. $IBB $IBBQ
2 · Reply
Peachtreegal
Peachtreegal Oct. 17 at 3:35 PM
$ARTV $IBBQ $BIB
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 17 at 3:27 PM
Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally $ARTV $IBBQ $BIB https://stocktwits.com/news/equity/markets/artiva-biotherapeutics-gets-price-target-hike-from-wedbush/ch6sW9tR38A
0 · Reply
BioRich
BioRich Aug. 22 at 3:45 PM
$ALT From Altimmune's 10-Q SEC Filing: PART II. OTHER INFORMATION Item 1. Legal Proceedings "Collier v. Altimmune, Inc., et al., Case No. 8:25-cv-02581 (D. Md.) (the “Collier Class Action”). The Collier Class Action alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact to the investing public including the plaintiff and class members, who purchased or otherwise acquired the Company’s common stock between August 10, 2023 and June 25, 2025, including relating to pemvidutide and our IMPACT Phase 2b trial of pemvidutide in MASH." https://ir.altimmune.com/node/17071/html#TOC $XBI $IBB $IBBQ
1 · Reply
BioRich
BioRich Aug. 21 at 3:30 PM
$ALT @Jacked_Nicholson Imagine being so delusional that you choose to disregard everything $ALT has done to you and placing that anger towards anyone else not left in the sandbox of bagholders. I've personally shared why $ALT was a terrible investment, why they will be subject to lawsuits and SEC investigations, as well as why no BP has legitimate (full value) interest in $ALT. They are dead money. Only way this moves is if WS wants it to move. They don't have Obesity, they don't have Fibrosis, they have shiny objects of no value in AUD and ALD and will continue to fail. MASH numbers looked good, but that's not enough. The concept and hope was great, the results do NOT support it. That's about as easy as I can explain it. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we learn. Let's make some money. Cheers! $XBI $IBB $IBBQ
0 · Reply
BioRich
BioRich Aug. 19 at 3:08 PM
$VVOS I think we see a run-up going into AH earnings. I really liked what I heard last call about their expansion and growth so I'm excited to see what they announce this go around. Another ST user turned me onto this gem several months ago and I've been happy with it ever since. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $IBB $IBBQ
0 · Reply
Shanthi_Rexaline
Shanthi_Rexaline Jul. 29 at 9:28 AM
AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheers https://stocktwits.com/news-articles/markets/equity/astrazeneca-q2-beats-on-cancer-drug-sales-maintains-guidance-shares-rise-premarket/cho9ppoR5U0 $AZN $IBB $IBBQ
0 · Reply